NewsBite

Exclusive

Start-up to sell ‘unapproved’ replica Ozempic, upending market

Nick Bonyhady
Nick BonyhadyTechnology writer

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Online weight loss brands Juniper and Pilot will soon begin selling replica Ozempic, defying health warnings from its manufacturer and medical regulators, as Australians face a year with the weight loss drug in vanishingly short supply.

The two brands, which are run by the $560 million Woolworths-backed telehealth start-up Eucalyptus, will have a version of the drug made at two Australian compounding pharmacies in a move that could upend the local market.

Loading...
Nick Bonyhady is a technology writer for the Australian Financial Review, based in Sydney. He is a former technology editor, industrial relations and politics reporter at the Sydney Morning Herald and Age. Connect with Nick on Twitter. Email Nick at nick.bonyhady@afr.com

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Latest In Technology

Fetching latest articles

Most Viewed In Technology

    Original URL: https://www.afr.com/technology/start-up-to-sell-unapproved-replica-ozempic-upending-market-20231212-p5er1b